Prestige Consumer Healthcare (PBH) earnings history
Most recent quarter
- Fiscal period
- Q1 2027
- Period end
- Jun 30, 2026
- EPS actual
- $0.98
- EPS estimate
- $0.88
- EPS surprise
- +11.19%
- Revenue surprise
- +6.14%
- Revenue
- $265.7M
- Revenue estimate
- $250.3M
- Reported
- Aug 6, 2026
Prestige Consumer Healthcare reported fiscal Q1 2027 results on August 6, 2026. Earnings per share were $0.98, ahead of the $0.88 estimate by 11.19%. Revenue of $265.7 million beat the $250.3 million consensus by 6.14%. Compared with fiscal Q1 2026, EPS rose about 3% from $0.95 and revenue rose about 6.5% from $249.5 million.
The longer record is steady. Annual EPS was $4.22 in fiscal 2023, $4.21 in fiscal 2024, $4.53 in fiscal 2025 and $4.39 in fiscal 2026, about 3% lower than the year before. Annual revenue stayed between $1.13 billion and $1.14 billion from fiscal 2023 to 2025, then eased about 4% to $1.09 billion in fiscal 2026. In fiscal 2025 and 2026, Q1 was the lowest-earning quarter and Q4 the highest. Fiscal Q4 2025 set the highs in the table at $1.32 per share and $296.5 million. Prestige beat the EPS estimate in 16 of the last 20 quarters, and twice in the last four.
Fiscal Q2 results came between November 2 and November 7 in each of the past five years. That points to early November 2026 for the next report. It will show whether the year-over-year gain in revenue continues.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q1 2027 | Aug 6, 2026 | $0.88 | $0.98 | +11.19% | $265.7M | SEC |
| Q4 2026 | May 13, 2026 | $1.39 | $1.23 | −11.51% | $281.6M | SEC |
| Q3 2026 | Feb 5, 2026 | $1.14 | $1.14 | −0.39% | $283.4M | SEC |
| Q2 2026 | Nov 6, 2025 | $0.97 | $1.07 | +10.35% | $274.1M | SEC |
| Q1 2026 | Aug 7, 2025 | $1.00 | $0.95 | −4.99% | $249.5M | SEC |
| Q4 2025 | May 8, 2025 | $1.30 | $1.32 | +1.66% | $296.5M | SEC |
| Q3 2025 | Feb 6, 2025 | $1.18 | $1.22 | +3.82% | $290.3M | SEC |
| Q2 2025 | Nov 7, 2024 | $1.08 | $1.09 | +0.50% | $283.8M | SEC |
| Q1 2025 | Aug 8, 2024 | $0.86 | $0.90 | +4.72% | $267.1M | SEC |
| Q4 2024 | May 14, 2024 | $1.14 | $1.02 | −10.46% | $277.0M | SEC |
| Q3 2024 | Feb 8, 2024 | $1.04 | $1.06 | +1.83% | $282.7M | SEC |
| Q2 2024 | Nov 2, 2023 | $1.07 | $1.07 | +0.25% | $286.3M | SEC |
| Q1 2024 | Aug 3, 2023 | $1.01 | $1.06 | +5.01% | $279.3M | SEC |
| Q4 2023 | May 4, 2023 | $1.04 | $1.07 | +2.90% | $285.9M | SEC |
| Q3 2023 | Feb 2, 2023 | $1.01 | $1.04 | +2.77% | $275.5M | SEC |
| Q2 2023 | Nov 3, 2022 | $1.00 | $1.02 | +1.83% | $289.3M | SEC |
| Q1 2023 | Aug 4, 2022 | $1.04 | $1.09 | +4.98% | $277.1M | SEC |
| Q4 2022 | May 5, 2022 | $0.89 | $0.91 | +2.63% | $266.9M | SEC |
| Q3 2022 | Feb 3, 2022 | $0.88 | $0.99 | +12.08% | $274.5M | SEC |
| Q2 2022 | Nov 4, 2021 | $0.99 | $1.02 | +3.37% | $276.2M | SEC |
Quarterly revenue
Frequently asked questions
When did Prestige Consumer Healthcare (PBH) last report earnings?
Prestige Consumer Healthcare last reported on Aug 6, 2026, covering fiscal Q1 2027.
Did PBH beat earnings estimates?
Yes. Prestige Consumer Healthcare reported EPS of $0.98 for Q1 2027 against a $0.88 estimate — a 11.19% beat.
How much revenue did PBH report last quarter?
Prestige Consumer Healthcare reported $265.7M in revenue for Q1 2027, against a consensus estimate of $250.3M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.